Mason Hannah D, Latour Yvonne L, Boughter Christopher T, Johnson Kory R, Maric Dragan, Dorrier Cayce E, Guedes Vivian A, Lai Chen, Duncker Patrick C, Johnson Alexis M, Manglani Monica, Gill Jessica M, Perl Daniel P, Meier-Schellersheim Martin, McGavern Dorian B
Viral Immunology and Intravital Imaging Section, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Bethesda, MD, USA.
Laboratory of Immune System Biology, Computational Biology Section, National Institute of Allergy & Infectious Diseases, NIH, Bethesda, MD, USA.
Nat Immunol. 2025 Jun 24. doi: 10.1038/s41590-025-02198-4.
Neurodegenerative diseases activate innate and adaptive immune responses that can either slow or accelerate disease progression. Here, we sought to define beneficial immune pressures that emerge during tauopathy development in mice and humans. Using mice that express mutant human tau in neurons, we observed that microglia slowed tauopathy development by controlling the spread of phosphorylated tau (pTau) in the central nervous system and blood. However, over time microglia converted into distressed antigen-presenting cells, acquired neuronal transcripts and were targeted by resident, clonally expanded CD8 T cells. These cells did not express traditional effector molecules, such as IFNγ, TNF or granzymes a/b/c, but instead deposited granzyme K (GZMK) onto microglia and were regulated by immune checkpoint proteins (TIGIT, PD-1), as blockade of TIGIT and PD-1 enhanced disease progression. GZMKCD8 T cells also targeted microglia in pTau-rich human brain lesions resulting from age, Alzheimer's disease or chronic traumatic encephalopathy. Deletion of CD8 T cells in mice promoted the emergence of distressed microglia containing neuronal transcripts, markedly enhanced pTau spread and accelerated neurological decline. These data demonstrate that GZMKCD8 T cells are a signature of tauopathy development and could potentially be harnessed to slow disease progression.
神经退行性疾病会激活先天性和适应性免疫反应,这些反应既可能减缓也可能加速疾病进展。在此,我们试图确定在小鼠和人类tau蛋白病发展过程中出现的有益免疫压力。利用在神经元中表达突变型人类tau蛋白的小鼠,我们观察到小胶质细胞通过控制磷酸化tau蛋白(pTau)在中枢神经系统和血液中的扩散来减缓tau蛋白病的发展。然而,随着时间的推移,小胶质细胞转变为功能失调的抗原呈递细胞,获得神经元转录本,并被驻留的、克隆性扩增的CD8 T细胞靶向。这些细胞不表达传统的效应分子,如IFNγ、TNF或颗粒酶a/b/c,而是将颗粒酶K(GZMK)沉积到小胶质细胞上,并受免疫检查点蛋白(TIGIT、PD-1)调控,因为阻断TIGIT和PD-1会加速疾病进展。GZMK CD8 T细胞也靶向因衰老、阿尔茨海默病或慢性创伤性脑病导致的富含pTau的人类脑损伤中的小胶质细胞。在小鼠中删除CD8 T细胞会促进含有神经元转录本的功能失调小胶质细胞的出现,显著增强pTau的扩散并加速神经功能衰退。这些数据表明,GZMK CD8 T细胞是tau蛋白病发展的一个特征,有可能被用于减缓疾病进展。